Literature DB >> 35093407

Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer.

Henrike Barbara Zech1, Joanna Berger2, Wael Yassin Mansour3, Lena Nordquist4, Clara Marie von Bargen5, Lara Bußmann2, Agnes Oetting1, Sabrina Christiansen1, Nikolaus Möckelmann6, Arne Böttcher2, Chia-Jung Busch7, Cordula Petersen4, Christian Betz2, Kai Rothkamm4, Malte Kriegs4, Sabrina Köcher1, Thorsten Rieckmann8.   

Abstract

BACKGROUND: HPV-positive head and neck squamous cell carcinoma of the oropharynx (OPSCC) are more sensitive towards radiation than HPV-negative OPSCC. Two main theories exist regarding the underlying mechanism. Stronger lymphocyte infiltration points to an enhanced immunogenicity, whereas data from HPV-positive HNSCC cell lines suggest an enhanced cellular radiosensitivity based on a defect in DNA double-strand break (DSB) repair. The critical limitation of the latter theory is that the evidence was largely derived from a small number of established HPV-positive HNSCC cell lines. METHODS AND MATERIALS: Fresh patient-derived OPSCC samples were cut in 400 µm sections and cultured on cell culture inserts. Slice cultures were irradiated, in part combined with ATM inhibition, and fixed and frozen after 2 and 24 h. DSBs were analyzed by quantification of 53BP1 foci in nuclei co-stained with the SCC marker p63 via immunofluorescence microscopy.
RESULTS: Ex vivo OPSCC tumor slice cultures maintained stable oxygenation and proliferation characteristics for at least 3 days. Areas of p63-positivity in immunofluorescence microscopy matched histologically confirmed tumor cell areas in serial sections, indicating the suitability of p63 as a tumor cell marker. p63-positive nuclei in HPV-positive OPSCC tissues (n = 14) showed profoundly elevated numbers of residual radiation-induced DSBs as compared to those from HPV-negative OPSCC (n = 12) (3 Gy: on average 4.9 vs. 1.2 foci per nucleus; p < 0.0001). Within the HPV-positive subgroup, samples derived from patients with a smoking history of less than 10 pack years demonstrated higher residual DSBs as compared to those derived from patients with 10 or more pack years (3 Gy: on average 6.5 vs. 3.2 foci per nucleus; p = 0.0105). Additional ATM inhibition resulted in a substantial increase in residual foci in all 4 HPV-negative samples tested but strikingly only in 2 out of 11 HPV-positive samples.
CONCLUSIONS: In summary, our data provide robust, cell line-independent experimental evidence for an intrinsic DSB repair deficiency in HPV-positive OPSCC, strongly suggesting a meaningful contribution to the enhanced clinical radiosensitivity. The reduced effectiveness of ATM inhibition indicates a defect in the ATM-orchestrated DNA damage response. Lower numbers of residual 53BP1 nuclear foci in the ex vivo assay may identify HPV-positive patients with effective DSB repair who should potentially be excluded from de-intensification approaches.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DNA double-strand break repair; Ex vivo culture; HPV; OPSCC; Radiation sensitivity

Mesh:

Substances:

Year:  2022        PMID: 35093407     DOI: 10.1016/j.radonc.2022.01.017

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

1.  A Lack of Effectiveness in the ATM-Orchestrated DNA Damage Response Contributes to the DNA Repair Defect of HPV-Positive Head and Neck Cancer Cells.

Authors:  Sabrina Köcher; Henrike Barbara Zech; Leonie Krug; Fruzsina Gatzemeier; Sabrina Christiansen; Felix Meyer; Ruth Rietow; Nina Struve; Wael Yassin Mansour; Malte Kriegs; Cordula Petersen; Christian Betz; Kai Rothkamm; Thorsten Rieckmann
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

Review 2.  In vitro models as tools for screening treatment options of head and neck cancer.

Authors:  Barbara Seliger; Ahmed Al-Samadi; Bo Yang; Tuula Salo; Claudia Wickenhauser
Journal:  Front Med (Lausanne)       Date:  2022-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.